Bringing dietary therapy for eosinophilic oesophagitis under scientific scrutiny
- PMID: 36863389
- DOI: 10.1016/S2468-1253(23)00041-9
Bringing dietary therapy for eosinophilic oesophagitis under scientific scrutiny
Conflict of interest statement
I declare participation on advisory boards for Regeneron/Sanofi, Dr Falk Pharma, GlaxoSmithKline, and Bristol Myers Squibb, and participation on a data safety monitoring board for AstraZeneca.
Comment on
-
One-food versus six-food elimination diet therapy for the treatment of eosinophilic oesophagitis: a multicentre, randomised, open-label trial.Lancet Gastroenterol Hepatol. 2023 May;8(5):408-421. doi: 10.1016/S2468-1253(23)00012-2. Epub 2023 Feb 28. Lancet Gastroenterol Hepatol. 2023. PMID: 36863390 Free PMC article. Clinical Trial.
Similar articles
-
Comparing elimination diet therapies for eosinophilic oesophagitis.Nat Rev Gastroenterol Hepatol. 2023 May;20(5):269. doi: 10.1038/s41575-023-00779-y. Nat Rev Gastroenterol Hepatol. 2023. PMID: 37012325 No abstract available.
-
[Eosinophilic gastrointestinal disorders].Rev Med Suisse. 2016 Aug 31;12(528):1430-1433. Rev Med Suisse. 2016. PMID: 28675283 Review. French.
-
Editorial: cooking up something new for diet therapy of eosinophilic oesophagitis.Aliment Pharmacol Ther. 2022 Oct;56(7):1205-1206. doi: 10.1111/apt.17190. Aliment Pharmacol Ther. 2022. PMID: 36071014 No abstract available.
-
Eosinophilic oesophagitis and type 2 inflammation multimorbidity: an opportunity for biologic treatment.Lancet Gastroenterol Hepatol. 2022 Sep;7(9):787-788. doi: 10.1016/S2468-1253(22)00177-7. Lancet Gastroenterol Hepatol. 2022. PMID: 35932768 No abstract available.
-
Eosinophilic Esophagitis: Incidence, Diagnosis, Management, and Future Directions.Gastroenterol Clin North Am. 2021 Dec;50(4):825-841. doi: 10.1016/j.gtc.2021.08.001. Epub 2021 Oct 6. Gastroenterol Clin North Am. 2021. PMID: 34717873 Review.
Publication types
MeSH terms
Supplementary concepts
LinkOut - more resources
Full Text Sources
Medical
